List of Tagrisso drug patents
Tagrisso is owned by Astrazeneca.
Tagrisso contains Osimertinib Mesylate.
Tagrisso has a total of 4 drug patents out of which 0 drug patents have expired.
Tagrisso was authorised for market use on 13 November, 2015.
Tagrisso is available in tablet;oral dosage forms.
Tagrisso can be used as treatment of patients with metastatic epidermal growth factor receptor (egfr) t790m mutation-positive non-small cell lung cancer (nsclc), who have progressed on or after egfr tki therapy; treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21l858r mutations; adjuvant therapy after tumor resection in patients with non-small cell lung cancer(nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19deletions or exon 21 l858r mutations.
The generics of Tagrisso are possible to be released after 02 January, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9732058 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(9 years from now) | |
| US11524951 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(9 years from now) | |
| US8946235 | ASTRAZENECA | 2-(2,4,5-substituted-anilino) pyrimidine compounds |
Aug, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10183020 | ASTRAZENECA | Pharmaceutical compositions comprising AZD9291 |
Jan, 2035
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 18, 2027 |
| New Indication (I) | Dec 18, 2023 |
Drugs and Companies using OSIMERTINIB MESYLATE ingredient
Market Authorisation Date: 13 November, 2015
Treatment: Treatment of patients with metastatic epidermal growth factor receptor (egfr) t790m mutation-positive non-small cell lung cancer (nsclc), who have progressed on or after egfr tki therapy; Treatment of...
Dosage: TABLET;ORAL
TAGRISSO family patents
16
United States
9
China
7
Israel
7
European Union
6
EA
6
Canada
6
Denmark
6
Spain
6
Singapore
6
Poland
5
Croatia
5
Portugal
5
Hong Kong
5
Slovenia
5
RS
5
Hungary
4
Korea, Republic of
4
Japan
4
Brazil
4
Taiwan
4
Lithuania
3
ME
3
Ukraine
3
United Kingdom
3
Argentina
2
Australia
2
Dominican Republic
2
New Zealand
2
Uruguay
2
Peru
2
Malaysia
2
Costa Rica
2
Nicaragua
2
Chile
2
Cyprus
2
Philippines
2
Mexico
2
Guatemala
1
Colombia
1
Ecuador
1
Cuba
1
San Marino
1
South Africa
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic